Cancer Immunology Research · 2019 · 47 citations · 35 references
Life SciencesImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesT Cell BiologyT Cell ExhaustionT Cell Responses To TumorsAntigen-specific T Cell ResponsesCd8 Positive T Cell ResponsesCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesMicrorna In CancerMicrorna-mediated Immune RegulationT Cell-mediated Tumor ControlT-cell Responses To Tumor Antigens
Abstract microRNAs are short noncoding RNAs that regulate protein expression posttranscriptionally. We previously showed that miR-155 promotes effector CD8+ T-cell responses. However, little is known about the regulation of miR-155 expression. Here, we report that antigen affinity and dose determine miR-155 expression in CD8+ T cells. In B16 tumors expressing a low-affinity antigen ligand, tumor-specific infiltrating CD8+ T cells showed variable miR-155 expression, whereby high miR-155 expression was associated with more cytokine-producing cells and tumor control. Moreover, anti–PD-1 treatment led to both increased miR-155 expression and tumor control by specific CD8+ T cells. In addition, miR-155 overexpression enhanced exhausted CD8+ T-cell persistence in the LCMV cl13 chronic viral infection model. In agreement with these observations in mouse models, miR-155 expression in human effector memory CD8+ T cells positively correlated with their frequencies in tumor-infiltrated lymph nodes of melanoma patients. Low miR-155 target gene signature in tumors was associated with prolonged overall survival in melanoma patients. Altogether, these results raise the possibility that high miR-155 expression in CD8+ tumor-infiltrating T cells may be a surrogate marker of the relative potency of in situ antigen-specific CD8+ T-cell responses.
35
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
E. John Wherry, Sang‐Jun Ha, Susan M. Kaech et al. · Immunity · 2007 · 2.1K citations
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Enfu Hui, Jeanne Cheung, Jing Zhu et al. · Science · 2017 · 1.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Mark E. Dudley, John R. Wunderlich, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text
Medicine, Immunology, Oncology +17
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
E. John Wherry, Sang‐Jun Ha, Susan M. Kaech et al. · Immunity · 2007 · 1.4K citations · Full text